Associated Genetic Biomarkers
CA9 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains CA9 status as an inclusion criterion, 1 is phase 1/phase 2 (1 open).
Trials with CA9 status in the inclusion eligibility criteria most commonly target pancreatic ductal adenocarcinoma .
The most frequent alteration to serve as an inclusion eligibility criterion is CA9 Expression .
Slc-0111 and gemcitabine are the most frequent therapies in trials with CA9 as an inclusion criteria .
Significance of CA9 in Diseases
Pancreatic Ductal Adenocarcinoma +
CA9 is an inclusion criterion in 1 clinical trial for pancreatic ductal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CA9 status and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.